Pharmacokinetic-pharmacodynamic modeling and simulation for in vivo bactericidal effect in murine infection model

Journal of Pharmaceutical Sciences

Volumn 97, Issue 4, 2008, Pages 1606-1614

  Katsube, Takayuki ^a   Yamano, Yoshinori ^a   Yano, Yoshitaka ^a,b  

^a SHIONOGI AND CO LTD   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Mathematical model; Pharmacodynamics; Pharmacokinetic (PK) pharmacodynamic (PD) models; Pharmacokinetics; Simulations

Indexed keywords

ANTIBIOTIC AGENT; CARBAPENEM; CILASTATIN; CILASTATIN PLUS IMIPENEM; CYCLOPHOSPHAMIDE; DORIPENEM; IMIPENEM; MEROPENEM; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; THIENAMYCIN DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; INSTITUTE FOR CANCER RESEARCH MOUSE; LUNG INFECTION; MATHEMATICAL MODEL; MINIMUM INHIBITORY CONCENTRATION; MODEL; MOUSE; NONHUMAN; PHARMACODYNAMICS; PSEUDOMONAS AERUGINOSA; ANIMAL; AREA UNDER THE CURVE; BIOLOGICAL MODEL; DISEASE MODEL; MICROBIOLOGICAL EXAMINATION;

ANIMALS; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BACTERIAL INFECTIONS; CARBAPENEMS; CILASTATIN; DISEASE MODELS, ANIMAL; FEMALE; IMIPENEM; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; THIENAMYCINS;

EID: 43249096035     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21062     Document Type: Article

References (41)

1. Meibohm B, Derendorf H. 2002. Pharmacokinetic/ pharmacodynamic studies in drug product development. J Pharm Sci 91:18-31.
2. Sheiner LB, Steimer JL. 2000. Pharmacokinetic/ pharmacodynamic modeling in drug development. Annu Rev Pharmacol Toxicol 40:67-95.
3. Zak O, O'Reilly T. 1993. Animal infection models and ethics - the perfect infection model. J Antimicrob Chemother 31:193-205.
4. Andes D, Craig WA. 2002. Animal model pharmacokinetics and pharmacodynamics: A critical review. Int J Antimicrob Agents 19:261-268.
5. Craig WA. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn Microbiol Infect Dis 22:89-96.
6. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12.
7. Leggett LE, Fantin B, Ebert S, Totsuka K, Vogelman B, Calame W, Mattie H, Craig WA. 1989. Comparative antibiotic dose-effect relations at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 159:281-292.
8. Miyazaki S, Okazaki K, Tsuji M, Yamaguchi K. 2004. Pharmacodynamics of S-3578, a novel cephem, in murine lung and systemic infection models. Antimicrob Agents Chemother 48:378-383.
9. Tanaka T, Aizawa K, Shimuzu A, Sakakibara S, Watabe H, Totsuka K. 2004. Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis. J Infect Chemother 10:76-85.
10. Yano Y, Oguma T, Nagata H, Sasaki S. 1998. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J Pharm Sci 87:1177-1183.
11. Robertson TB. 1923. The chemical basis of growth and senescence. Philadelphia and London: Lippincott.
12. Jusko WJ. 1973. A pharmacodynamic model for cell-cycle specific chemotherapeutic agents. J Pharmacokinet Biopharm 1:175-200.
13. Li RC, Nix DE, Schentag JJ. 1994. Pharmacodynamic modeling of bacterial kinetics: β-lactam antibiotics against Escherichia coli. J Pharm Sci 83: 970-975.
14. Tsuji A, Hamano S, Asano T, Nakashima E, Yamana T, Mitsuhashi S. 1984. Microbial kinetics of β-lactam antibiotics against Escherichia coli. J Pharm Sci 73:1418-1422.
15. Zhi J, Nightingale CH, Quintiliani R. 1988. Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm 16:355-375.
16. Fujimura T, Kimura Y, Miwa H, Yoshida I, Higashiyama I, Jinushi Y, Munekage T, Kuroda N, Doi M, Nishikawa T, Yamano Y. 2005. In vitro antibacterial activity of doripenem, a novel parenteral carbapenem. Jpn J Chemother 53:57-70.
17. Fujimura T, Yamano Y, Yoshida I, Shimada J, Kuwahara S. 2003. In vitro activity of S-3578, a new broad-spectrum cephalosporin active against methicillin-resistant staphylococci. Antimicrob Agents Chemother 47:923-931.
18. Gerber AU, Feller-Segessenmann C. 1985. In-vivo assessment of in-vitro killing patterns of Pseudomonas aeruginosa. J Antimicrob Chemother 15: 201-206.
19. Zhanel GG, Karlowsky JA, Hoban DJ, Davidson RJ. 1991. Antimicrobial activity of subinhibitory concentration of aminoglycosides against Pseudomonas aeruginosa as determined by the killing-curve method and the postantibiotic effect. Chemotherapy 37:114-121.
20. Miwa H, Kimura Y, Jinushi Y, Fujimura T, Nishikawa T, Munekage T, Kuroda N, Yamano Y, Tsuji M, Okazaki K, Sato T, Matsuda H. 2005. Antipseudomonal activity of doripenem, a novel parenteral carbapenem antibiotic. Jpn J Chemother 53:80-91.
21. National Committee for Clinical Laboratory Standards. 1990. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed., Villanova, PA: Approved standard M7-A2, National Committee for Clinical Laboratory Standards.
22. Akaike H. 1974. A new look at the statistical model identification. IEEE Trans Automat Contr 19:716-718.
23. Yamaoka K, Nakagawa T, Uno T. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175.
24. Kneer J. 1993. Relevance of antibiotics tissue penetration in treating respiratory tract infections. Respiration 60:32-37.
25. Liu P, Fuhrherr R, Webb AI, Obermann B, Derendorf H. 2005. Tissue penetration of cefpodoxime into the skeletal muscle and lung in rats. Eur J Pharm Sci 25:439-444.
26. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Models of tissue penetration and their meaning. Antimicrob Agents Chemother 35: 1947-1952.
27. Nix DE, Goodwin SD, Peloquin CA, Rotella DL, Schentag JJ. 1991. Antibiotic tissue penetration and its relevance: Impacts of tissue penetration on infection response. Antimicrob Agents Chemother 35:1953-1959.
28. Yamaoka K, Nakagawa T. 1983. A nonlinear least squares program on differential equations, MULTI(RUNGE), for microcomputers. J Pharma-cobiodyn 6:595-606.
29. Craig WA. 1993. Postantibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 31:149-158.
30. Craig WA, Redington J, Ebert SC. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 27: 29-40.
31. Vogelman B, Gudmundsson S, Turnidge J, Leggett J, Craig WA. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J Infect Dis 157:287-298.
32. de la Pena A, Grabe A, Rand KH, Rehak E, Gross J, Thyroff-Friesinger U, Muller M, Derendorf H. 2004. PK-PD modeling of the effect of cefaclor on four different bacterial strains. Int J Antimicrob Agents 23:218-225.
33. Delacher S, Derendorf H, Hollenstein U, Brunner M, Joukhadar C, Hofmann S, Georgopoulos A, Eichler HG, Muller M. 2000. A combined in vivo pharmacokinetic-in vitro pharmacodynamic approach to simulate target pharmacodynamics of antibiotics in humans. J Antimicrob Chemother 46:733-739.
34. Keil S, Wiedemann B. 1995. Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution models. Antimicrob Agents Chemother 39: 1054-1058.
35. Liu P, Rand KH, Obermann B, Derendorf H. 2005. Pharmacokinetic- pharmacodynamic modeling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int J Antimicrob Agents 25:120-129.
36. Nolting A, Dalla Costa T, Rand KH, Derendorf H. 1996. Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro. Pharm Res 13:91-96.
37. Regoes RR, Wiuff C, Zappala RM, Garner KN, Baquero F, Levin BR. 2004. Pharmacodynamic functions: A multiparameter approach to the design of antibiotic treatment regimens. Antimicrob Agents Chemother 35:1953-1959.
38. Garrett ER. 1978. Kinetics of antimicrobial action. Scand J Infect Dis Suppl 14:54-85.
39. Araki H, Ogake N, Tsuneda R, Minami S, Watanabe Y, Tamai I, Tsuji A. 2002. Muscle distribution of antimicrobial agents after a single intravenous administration to rats. Drug Metab Pharmacokinet 17:237-244.
40. Deguchi Y, Terasaki T, Yamada H, Tsuji A. 1992. An application of microdialysis to drug tissue distribution study: In vivo evidence for free-ligand hypothesis and tissue binding of β-lactam antoibiotics in interstitial fluids. J Pharmacobiodyn 15:79-89.
41. Liu P, Muller M, Derendorf H. 2002. Rational dosing of antibiotics: The use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 19:285-290.